Rapamycin for longevity: what is actually known?

A transplant drug becomes a biohacker staple

Rapamycin, also called sirolimus, is an approved prescription drug used to prevent organ transplant rejection, treat a rare lung disease, and coat certain heart stents. None of that stopped it from becoming one of the most talked-about compounds in longevity circles, taken off-label, in low weekly doses, by biohackers convinced it will slow their own aging. Bryan Johnson has used it publicly. Online longevity forums treat it as close to settled science. The animal research behind that confidence is real. Whether it translates to a healthy person popping a pill once a week is a different, much less settled question.

The mouse evidence, which is genuinely strong

Start with what is not in dispute. The National Institute on Aging's Interventions Testing Program, running independent trials across three research sites, found rapamycin reliably extends mouse lifespan, and the effect replicates. A 2009 study found it extended median lifespan even when feeding began at 600 days old, comparable to starting treatment as a 60-year-old human, a genuinely encouraging detail since most anti-aging interventions only work if started young. A 2014 follow-up tested a range of doses and found median lifespan increases from 13 to 26 percent depending on dose and sex, with the effect showing up consistently across all three testing sites. Few interventions in the aging literature have been replicated this cleanly. This is one of the strongest empirical cases science has for any longevity compound.

The first real human trial, and what it actually found

What does not exist, despite years of enthusiastic use, is a human trial showing rapamycin extends human lifespan, for the obvious reason that such a trial would take decades. The closest thing so far is PEARL, a crowdfunded, placebo-controlled trial published in 2025 that gave 114 adults, mostly in their 50s and 60s, either a placebo or one of two low weekly rapamycin doses for 48 weeks. Its primary target, visceral fat, showed no significant difference between groups, meaning the trial missed its main goal. Some secondary findings were genuinely positive, women in the higher-dose group gained lean muscle mass and reported less pain, but the benefits were modest and concentrated in one sex. Matt Kaeberlein, a University of Washington biogerontologist who has studied rapamycin for years, summed up the state of human evidence bluntly: there's signal there, but there's a whole lot of noise. Even a researcher this invested in the drug's promise stops well short of calling the human case proven.

The side effects are not hypothetical

Rapamycin is not a supplement with a clean safety record, it is an immunosuppressant with an FDA boxed warning, the agency's strongest label alert, for increased infection risk and possible lymphoma. Its prescribing information lists hypertriglyceridemia in up to 57 percent of patients, high cholesterol in up to 46 percent, mouth sores, impaired wound healing and elevated diabetes risk. Johnson's own experience is a real-world illustration: he stopped taking it in 2024 after developing intermittent skin infections, high glucose and abnormal blood lipids, exactly the pattern the label predicts. PEARL's low, once-weekly, short-term dosing did not show these effects over one year, which is reassuring for that specific protocol, but it is a meaningfully smaller exposure than continuous higher-dose use, and nobody has studied what years of off-label biohacker dosing does.

Our take

Rapamycin has the best animal longevity data of almost anything discussed in this space, and that is worth taking seriously rather than dismissing. It is also a real immunosuppressant drug with a boxed warning, no completed human lifespan trial, and a first human healthspan trial that missed its own primary target. The gap between those two facts is exactly where the current biohacking trend is standing, and it is a wider gap than the enthusiasm online suggests, similar to the story we found looking at NMN and NAD+ supplements, another longevity molecule with strong animal promise and no proven human benefit. If you are going to explore this, do it with a doctor watching your bloodwork, not a supplement aisle.

This is general information, not medical advice. Talk to a clinician before changing anything, especially if you are pregnant, nursing, or managing a condition.